VU Venture Partners

"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."

"We are thrilled to have the support of such a diverse and experienced group of investors. This additional funding will enable us to continue the significant progress we have made off the back of our Series A and expedite the advancement of our cloud-based solutions for the metaverse. Our objective is to bridge physical and virtual worlds to improve decision-making, support the creator economy and, ultimately, enhance the quality of life in the real world. We believe that the metaverse’s true success and widespread adoption depend on the creators’ ability to build their own experiences at scale, using open and robust metaverse-as-a-service technologies."